Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Cost of Illness of Chronic Hepatitis B Infection in Vietnam
Authors: Hong Anh T Tu
Herman J. Woerdenbag
Arthorn Riewpaiboon
Sumit Kane
Diep M. Le
Maarten J. Postma
Shu Chuen Li
University of Groningen
Hanoi University
Mahidol University
Royal Tropical Institute - KIT
Bach Mai Hospital
University of Newcastle, Australia
Keywords: Economics, Econometrics and Finance;Medicine;Pharmacology, Toxicology and Pharmaceutics
Issue Date: 1-May-2012
Citation: Value in Health Regional Issues. Vol.1, No.1 (2012), 23-28
Abstract: To estimate the total financial burden of chronic hepatitis B virus (HBV) infection for Vietnam by quantifying the direct medical, the direct nonmedical, and indirect costs among patients with various stages of chronic HBV infection. Direct medical cost data were retrieved retrospectively from medical histories of inpatients and outpatients in 2008 from a large referral hospital in Hanoi, Vietnam. Direct nonmedical and indirect costs data were obtained from face-to-face interviews of outpatients from the same hospital. The treatment cost per patient per chronic HBV infection stage was multiplied by the total estimated patients in Vietnam to get the total cost of illness for the nation. Nationally, the total cost attributable to chronic HBV infection and its complications in 2008 was estimated to be approximately US $4.4 billion, with the direct medical cost accounting for about 70% of that estimate. The cost of antivirals was the major cost driver in treating chronic HBV infection. The per-patient total annual direct medical cost increased with the severity of the disease, with the estimated costs for chronic HBV infection and hepatocellular carcinoma as US $450.35 and US $1883.05, respectively. When compared with the 2008 per-capita gross domestic product of ∼US $1024, the financial burden of treating chronic HBV infection is very high in Vietnam. This study confirmed that chronic HBV infection poses a significant financial burden for the average patient and that lacking treatment would become a social i ssue in Vietnam. Although HBV vaccination has been universally implemented, more health care investment and the greater availability of affordable medications are still needed to attain equity in proper treatment for patients with HBV infection. © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR).
ISSN: 22121099
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.